What question did this study set out to answer?

April 15, 2026AntibodiesOpen Access

Development of a Human IgG1 Monoclonal Antibody Targeting Transferrin Receptor 1 for Antitumor Drug Delivery

View Full Paper

Ask AI

Bookmark

Authors

Develops a monoclonal antibody targeting transferrin receptor 1 for drug delivery in tumors, suggesting high potential for cancer therapies.

The research aims to develop and evaluate a human IgG1 monoclonal antibody targeting transferrin receptor 1 for effective antitumor drug delivery.
Isolated T8scFv antibody from a human scFv phage display library through stringent biopanning.
Converted T8scFv into a full-length IgG1 antibody (T8IgG1) and characterized binding kinetics using Octet biolayer interferometry.
Assessed cellular binding and internalization with flow cytometry and immunofluorescence microscopy.
Conjugated T8IgG1 to a diphtheria toxin fusion protein to evaluate internalization-dependent cytotoxicity.
T8scFv showed nanomolar affinity for TfR1 (KD = 214 ± 1 nM), which improved in the IgG1 format (KD = 18.5 ± 0.1 nM).
T8IgG1 specifically targeted and internalized through TfR1 on tumor cells.
The T8IgG1-DT3C complex significantly reduced cell viability and induced apoptosis in K562 cells in vitro.

Ji et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Develops a monoclonal antibody targeting transferrin receptor 1 for drug delivery in tumors, suggesting high potential for cancer therapies.